|
|
|
|
Rugby lad Gareth Jenkins buried seven months after bone cancer diagnosis
A TEENAGE rugby star was buried yesterday - just seven months after he was diagnosed with bone cancer.Gareth Jenkins - a Welsh Under-18 international - did not know he was dying when he turned out for his country against...
|
|
|
Young Wales player's cancer death
Gareth Jenkins' funeral takes place in Swansea on Tuesday Friends of a youth rugby international are being asked to wear Welsh tops at his funeral in Swansea.Gareth Jenkins was diagnosed with a form of bone cancer just weeks...
|
|
|
Rotary helps family of girl with cancer
ROCHESTER The Rochester Rotary Club presented city Economic Development Manager Karen Pollard and her family with a check for $9,392.83 at their meeting on Nov.The money was raised at last month's Pollard Family Fundraiser, held by the...
|
|
|
Family clings together after son gets cancer, house is robbed
The past two years have been hard for Maria Campos and her family.Campos, a single mother of three, said the hard times started after her divorce in March 2007. On Sept. 22, the biggest shock came when her son's cancer was...
|
|
|
Teens 'miss out' on cancer trials
Young people with cancer tend to do better if they are in clinical trials Teenagers with cancer are not being included in UK clinical trials which could improve their chances of survival, according to researchers.Trials from...
|
|
|
Kicking cancer's butt
LEWISTON - The foe is formidable.And nothing short of a superhero is needed to take it on. That's the idea behind a new comic book created by Lewiston artist Ty Wakefield. 'Tonight we had a huge premier party for my new comic book...
|
|
|
Press Release: Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue
SAN MARINO, Calif., Nov.25, 2008 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as...
|
|
|
Epeius reports encouraging results from Phase I/II and II sarcoma studies
Patients received repeated infusions of Rexin-G intravenous over a period up to nine months.Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth, the company said. Analysis...
|
|
|
Kicking cancer's butt
LEWISTON - The foe is formidable.And nothing short of a superhero is needed to take it on. That's the idea behind a new comic book created by Lewiston artist Ty Wakefield. 'Tonight we had a huge premier party for my new comic book...
|
|
|
New Cancer Treatment Shrinks Pancreatic Tumor
The tumor reduction correlated with resolution of the patient's symptoms of pain and digestive problems.'The cancer isn't gone,' emphasized NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell The patient's daughter...
|
|
|
New Cancer Treatment Shrinks Pancreatic Tumor
The patient's daughter discussed her father's treatment, saying 'He began the NeoPlas treatment after he became too ill to complete his final course of radiation following chemotherapy.' She added, 'Since then, he has been able to resume...
|
|
|
Family of child with bone cancer seeks help for medical expenses
The 7-year-olds mother, Jenny Kitchens, said everyone told her it was just growing pains.Then one night he stayed awake all night crying, said Kitchens, 31. Now Junior, as his family calls him, is being treated for an aggressive disease...
|
|
|
Family of child with bone cancer seeks help for medical expenses
(Muskogee Phoenix - McClatchy-Tribune Information Services via COMTEX) -- Charles Moham Jr.complained of his leg hurting. The 7-year-old's mother, Jenny Kitchens, said everyone told her it was just growing pains. 'Then one night he...
|
|
|
Epeius reports encouraging results from Phase I/II and II sarcoma studies
Epeius Biotechnologies has announced the positive results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.Patients received repeated infusions of Rexin-G intravenous...
|
|
|
PharmaMar gets 'Supporting A Cure In Our Time' award from SFA
PharmaMar has received the Award 'Supporting A Cure In Our Time' from the Sarcoma Foundation of America (SFA) for its 'support in the search for an effective cure for soft tissue sarcomas', goal of the foundation, during the...
|
|
|
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosar
/PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr.Sant P. Chawla, principal...
|
|
|
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosar
SAN MARINO, Calif., Nov.20 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr.
|
|
|
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosar
SAN MARINO, Calif., Nov.20 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr.
|
|
|
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosar
Phase I/II & Confirmatory Phase II Studies SAN MARINO, Calif., Nov.20 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue...
|
|
|
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosar
SAN MARINO, Calif., Nov.20 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr.
|
|
|
Epeius Biotechnologies announces results of Rexin-G in chem-resistant metastatic soft tissue sarcoma and osteo
Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr.Sant P. Chawla, principal investigator, at...
|
|
|
Epeius Biotechnologies Corporation Release: Rexin-G Controls Tumor Growth and Improves Survival in Chemotherap
SAN MARINO, Calif., Nov.20 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr.
|
|
|
Ligand Collaborator GlaxoSmithKline Receives FDA Approval for Promacta
- Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding.PROMACTA has been shown in pre-clinical research and clinical...
|
|
|
Ligand Collaborator GlaxoSmithKline Receives FDA Approval for PROMACTA
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding.PROMACTA has...
|
|
|
Ligand Collaborator GlaxoSmithKline Receives FDA Approval for PROMACTA®
Ligand Pharmaceuticals Incorporated (News) (NASDAQ: LGND) Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding.
|
